+1 (817) 546-4770

US Health Regulator Flags Concerns at Medtronics Diabetes Business

Academic Anxiety?

Get an original paper within hours and nail the task

156 experts online

The U.S. health regulator has issued a warning letter to Medtronic highlighting certain concerns related to medical device quality management at its diabetes business, the company said on Wednesday.Medtronic’s shares were down 6% at $104.95 in early trading, hitting their lowest in over a year.webmd.ads2.defineAd({id:’ads-pos-1122′,pos: 1122});The Food and Drug Administration’s (FDA) letter focused on inadequacies in areas including risk assessment, complaint handling and device recalls at Medtronic’s facility in Northridge, California, the company said.The company is speedily addressing the FDA’s concerns and reviewing its actions with the agency, it added.

webmd.ads2.defineAd({id:’ads-pos-520′,pos: 520});Medtronic, in a filing, said it did not expect an impact to its third quarter or full-year 2022 adjusted profit outlook issued previously.

webmd.ads2.defineAd({id:’ads-pos-1520′,pos: 1520});However, at the diabetes unit, it has forecast a decline in organic revenue citing uncertainty on timing of U.S. product approvals, among other things. For the unit, it expects a decline in the high-single digit range for the third quarter and mid-single digits range for fiscal 2022, compared with previous guidance of mid- and low-single digit declines respectively.”The hit to financials isn’t great, but worse is likely the hit to investor sentiment,” said J.P. Morgan analyst Robbie Marcus, adding that Medrontic’s diabetes unit was already lagging behind rivals and the warning letter is likely to exacerbate the problem.Medtronic said the letter, received earlier this month, followed an inspection in July related to recalls of MiniMed 600 insulin infusion pumps and a remote controller device for certain other pumps.

webmd.ads2.defineAd({id:’ads-pos-141′,pos: 141});The medical device maker in 2019 had initiated a recall of the MiniMed 600 pumps used by diabetes patients to replace those with damaged or missing clear retainer rings which lock a cartridge holding the insulin into the pump.The company had later announced it would replace all pumps with clear retainer rings with another design, regardless of whether they were damaged or not.


Reuters Health Information © 2021 Reuters Ltd.
Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Cite this: US Health Regulator Flags Concerns at Medtronic’s Diabetes Business – Medscape – Dec 16, 2021.


id: ‘ads-pos-904’,
pos: 904

id: ‘ads-pos-906’,
pos: 906

id: ‘ads-pos-907’,
pos: 907

Need an essay written specifically to meet your requirements?

Choose skilled experts on your subject and get an original paper within your deadline

156 experts online

Your time is important. Let us write you an essay from scratch

Tips and Tricks from our Blog

11174 Introduction To Management

Free Samples 11174 Introduction To Management .cms-body-content table{width:100%!important;} #subhidecontent{ position: relative; overflow-x: auto; width: 100%;} 11174 Introduction

Read More »